

Please type a plus sign (+) inside this box → +

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	09/914,708
				Filing Date	August 31, 2001
				First Named Inventor	BOYD, Michael R.
				Group Art Unit	1617
				Examiner Name	Shengjun Wang
				Attorney Docket Number	213045
Sheet	1	of	4	Client Reference No.	E-244-1997/3-US-06

U.S. PATENT DOCUMENTS					
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication
		Application or Patent Number	Kind Code		

Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
AA	WO 99/05136	A1	The United States of America	Feb. 04, 1999				
AB	WO 00/51589	A2	The United States of America	Sep. 08, 2000				
AC	WO 00/51589	A3	The United States of America	Jul. 12, 2001				

OTHER - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.			
AD	Akifusa et al., <i>Exp. Cell Res.</i> , 238, 82-89 (1998)				Translation Yes No**
AE	Aldridge et al., <i>J. Chem. Soc.</i> , 1623-1627 (1971)				
AF	Altan et al., <i>J. Exp. Med.</i> , 187, 1583-1598 (1998)				
AG	Arabshahi et al., <i>Tetrahedron Lett.</i> , 29, 10, 1099-1102 (1988)				
AH	Benderla et al., <i>Int. J. Onco.</i> , 12, 711-715 (1998)				
AI	Benslimane et al., <i>J. Natural Prod.</i> , 51, 3, 582-583 (1988)				
AJ	Blair et al., <i>Science</i> , 245, 855-857 (1987)				
AK	Bowman et al., <i>Proc. Natl. Acad. Sci. USA</i> , 85, 7972-7976 (1988)				
AL	Boyd and Paull, <i>Drug Dev. Res.</i> , 34, 91-109 (1995)				
AM	Boyd, <i>Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval</i> (Teicher, B.A., ed.) Totowa, NJ: Humana Press, Inc., pp. 23-42 (1997)				
AN	Boyd, <i>Current Therapy in Oncology</i> (Niederhuber, ed.), Philadelphia: B.C. Decker, Inc., pp. 11-22 (1993)				
AO	Boyd, <i>Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development</i> (Valerio, F.A. et al., eds.) Amsterdam: Kluwer Academic Publishers, pp. 11-34 (1992)				
AP	Boyd: <i>Cancer: Principles and Practice of Oncology Updates</i> (DeVita, V.T., Jr., et al., eds.) Philadelphia: Lippincott, 3, 11-22 (1989)				
AQ	Broady et al., <i>J. Chem. Soc. Chem. Commun.</i> 708-711 (1991)				
AR	Carmeli et al., <i>J. Nat. Prod.</i> , 53, 6, 1533-1542 (1990)				
AS	Caroll et al., <i>Aust. J. Chem.</i> , 46, 825-832 (1993)				
AT	Chan et al., <i>Anal. Biochem.</i> , 157, 375-380 (1986)				
AU	Charan et al., <i>Tetrahedron</i> , 52, 27, 9111-9120 (1996)				
AV	Choukchou-Braham et al., <i>Tetrahedron Lett.</i> , 35, 23, 3949-3952 (1994)				
AW	Collins, <i>Cancer Chemotherapy: Principles and Practice</i> , 2, J.B. Lippincott, 16-31 (1990)				
AX	Copp et al., <i>Tetrahedron Lett.</i> , 30, 28, 3703-3706 (1989)				
AY	Dale et al., <i>J. Am. Chem. Soc.</i> , 95, 512-519 (1973)				

Examiner Signature	Date Considered
--------------------	-----------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

4

<i>Complete if Known</i>	
Application Number	09/914,708
Filing Date	August 31, 2001
First Named Inventor	BOYD, Michael R.
Group Art Unit	1617
Examiner Name	Shengjun Wang
Attorney Docket Number	213045

Client Reference No. E-244-1997/3-US-06

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation Yes No ⁺⁺
AZ		D'Auria et al., <i>Tetrahedron</i> , 49 , 38, 8657-8664 (1993)	
BA		David et al., <i>Exp. Opin. Invest. Drugs</i> , 4 , 725-740 (1995)	
BB		Dekker et al., <i>J. Antibiotics</i> , 51 , 14-20 (1998)	
BC		Doi et al., <i>Tetrahedron</i> , 50 , 29, 8651-8656 (1994)	
BD		Dröse et al., <i>Biochemistry</i> , 32 , 3902-3906 (1993)	
BE		Dröse et al., <i>J. Exp. Biol.</i> 200 , 1-8 (1997)	
BF		Dürgnat et al., <i>Helvetica Chim. Acta</i> , 76 , 222-240 (1993)	
BG		Erickson et al., <i>J. Org. Chem.</i> , 62 , 23, 8188-8192 (1997)	
BH		Farina et al., <i>Therapeutic Focus</i> , 4 , 4, 163-172 (1999)	
BI		Faulkner et al., <i>Marine Nat. Prod.</i> , 9 , 497-539 (1992)	
BJ		Fenical et al., <i>Marine Tech. Soc.</i> , 388-394 (1974)	
BK		Finbow et al., <i>Biochem. J.</i> , 324 , 697-712 (1997)	
BL		Forgac, <i>Physiological Rev.</i> , 69 , 765-796 (1989)	
BM		Fu et al., <i>J. Am. Chem. Soc.</i> , 116 , 12125-12126 (1994)	
BN		Furstner et al., <i>Tetrahedron</i> , 55 , 8215-8230 (1999)	
BO		Fusetani et al., <i>Tetrahedron Lett.</i> , 30 , 21, 2809-2812 (1989)	
BP		Gagliardi et al., <i>J. Med. Chem.</i> , 41 , 1883-1893 (1998)	
BQ		Gagliardi et al., <i>J. Med. Chem.</i> , 41 , 1568-1573 (1998)	
BR		Galinis et al., <i>J. Org. Chem.</i> , 62 , 8968-8969 (1997)	
BS		Gerard et al., <i>J. Exp. Biol.</i> , 201 , 21-31 (1998)	
BT		Ghosh et al., <i>Tetrahedron Lett.</i> , 39 , 8803-8804 (1998)	
BU		Gordon et al., <i>J. Org. Chem.</i> , 49 , 97-100 (1984)	
BV		Grever et al., <i>Cancer Principles and Practice of Oncology</i> , 5th Ed. (Devita et al., eds.) Philadelphia: Lippincott-Raven, pp. 385-394 (1977)	
BW		Guella et al., <i>Helvetica Chim. Acta</i> , 70 , 621-628 (1987)	
BX		Hall et al., <i>Bone and Mineral</i> , 27 , 159-166 (1994)	
BY		Hall et al., <i>Inflamm. Res.</i> , 45 , 1-9 (1996)	
BZ		Howard et al., <i>Tetrahedron Lett.</i> , 46 , 4449-4452 (1979)	
CA		Ishii et al., <i>J. Antibiot.</i> , 48 , 12-20 (1995)	
CB		Jaspars et al., <i>J. Org. Chem.</i> , 59 , 3253-3255 (1994)	
CC		Jensen et al., <i>J. Org. Chem.</i> , 37 , 10, 1639-1647 (1972)	
CD		Johnston et al., <i>J. Med. Chem.</i> , 13 , 5, 941-944 (1970)	
CE		Kaneko et al., <i>Tetrahedron Lett.</i> , 35 , 4107-4110 (1994)	
CF		Keeling et al., <i>Ann. New York Acad. Sci.</i> , 834 , 600-608 (1997)	
CG		Keman et al., <i>J. Org. Chem.</i> , 53 , 5014-5020 (1988)	
CH		Keman et al., <i>Tetrahedron Lett.</i> , 28 , 25, 2809-2812 (1987)	
CI		Kim et al., <i>J. Natural Prod.</i> , 56 , 10, 1813-1816 (1993)	
CJ		Kim et al., <i>J. Org. Chem.</i> , 64 , 153-155 (1999)	
CK		Kinoshita et al., <i>FEBS Lett.</i> , 337 , 221-225 (1994)	

Examiner Signature	Date Considered
--------------------	-----------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patient, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box → +

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of

4

<i>Complete if Known</i>	
Application Number	09/914,708
Filing Date	August 31, 2001
First Named Inventor	BOYD, Michael R.
Group Art Unit	1617
Examiner Name	Shengjun Wang
Attorney Docket Number	213045

Client Reference No. E-244-1997/3-US-06

OTHER - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation Yes No**
CL		Kinoshita et al., <i>FEBS Lett.</i> , 398 , 61-66 (1996)	
CM		Kobayashi et al., <i>J. Natural Prod.</i> , 56 , 5, 787-791 (1993)	
CN		Kobayashi et al., <i>J. Org. Chem.</i> , 59 , 255-257 (1994)	
CO		Kobayashi et al., <i>Tetrahedron</i> , 51 , 13, 3727-3736 (1995)	
CP		Kunze et al., <i>J. Antibiotics</i> , 51 , 1075-1080 (1998)	
CQ		Leclerc et al., <i>Tetrahedron Lett.</i> , 50 , 84 65-8488 (1994)	
CR		Manabe et al., <i>J. Cell Physiol.</i> , 157 , 445-452 (1993)	
CS		Marquardt et al., <i>J. Natl. Cancer Inst.</i> , 83 , 1098-1102 (1991)	
CT		Martinez-Zagulian et al., <i>Am. J. Physiol.</i> , 265 , C1015-C1029 (1993)	
CU		Martinez-Zagulian et al., <i>Ann. NY Acad. Sci.</i> , 671 , 478-480 (1992)	
CV		Martinez-Zagulian et al., <i>Am. J. Physiol.</i> , 276 , 196-205 (1998)	
CW		Matsunaga et al., <i>J. Am. Chem. Soc.</i> , 108 , 847-849 (1986)	
CX		McKee et al., <i>J. Org. Chem.</i> , 63 , 7805-7810 (1998)	
CY		Mellman et al., <i>Ann. Rev. Biochem.</i> , 55 , 663-699 (1986)	
CZ		Mohamadi et al., <i>J. Computat. Chem.</i> , 11 , 440-467 (1990)	
DA		Monks et al., <i>J. Natl. Cancer Inst.</i> , 83 , 757-766 (1991)	
DB		Montcourier et al., <i>Clin. Exp. Metastasis</i> , 15 , 382-392 (1997)	
DC		Montcourier et al., <i>J. Cell Sci.</i> , 107 , 2381-2391 (1994)	
DD		Moriyama et al., <i>J. Biochem.</i> , 115 , 213-218 (1994)	
DE		Murray et al., <i>Aust. J. Chem.</i> , 48 , 1253-1266 (1995)	
DF		Nelson, <i>TIPS</i> , 12 , 71-75 (1991)	
DG		Nishihara et al., <i>Biochem Biophys. Res. Commun.</i> , 212 , 255-262 (1995)	
DH		Oh et al., <i>J. Org. Chem.</i> , 54 , 4499-4503 (1989)	
DI		Ohkuma et al., <i>In Vitro Cell Devel. Biol.</i> , 29A , 862-866 (1993)	
DJ		Ohta et al., <i>J. Pathol.</i> , 185 , 324-330 (1998)	
DK		Ohtani et al., <i>J. Org. Chem.</i> , 56 , 1296-1297 (1991)	
DL		Parameswaran et al., <i>Chemical Abstracts</i> , 120 , 600 (1994)	
DM		Pauli et al., <i>Cancer Chemotherapeutic Agents</i> (Foye, ed.), Washington, D.C.: American Chemical Society Books, 9-45. (1995)	
DN		Pauli et al., <i>Cancer Res.</i> , 52 , 3892-3900 (1992)	
DO		Perona et al., <i>Nature</i> , 334 , 438-440 (1988)	
DP		Rashid et al., <i>J. Nat. Prod.</i> , 58 , 7, 1120-1125 (1995)	
DQ		Rochfort et al., <i>Aust. J. Chem.</i> , 49 , 1217-1219 (1996)	
DR		Roesener et al., <i>J. Am. Chem. Soc.</i> , 108 , 846-847 (1986)	
DS		Rovinski et al., <i>J. Natural Prod.</i> , 47 , 3, 557 (1984)	
DT		Rubinstein et al., <i>J. Natl. Cancer Inst.</i> , 82 , 1113-1118 (1990)	
DU		Sausville, <i>Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval</i> (Teicher, B.A., ed.) Totowa, NJ: Humana Press, Inc., pp. 217-226 (1997)	
DV		Shimojima et al., <i>J. Med. Chem.</i> , 26 , 1370-1374 (1983)	

Examiner Signature	Date Considered
--------------------	-----------------

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Please type a plus sign (+) inside this box →

Substitute for form 1449A/B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/914,708
(Use as many sheets as necessary)				Filing Date	August 31, 2001
				First Named Inventor	BOYD, Michael R.
				Group Art Unit	1617
				Examiner Name	Shengjun Wang
				Attorney Docket Number	213045
Sheet	4	of	4	Client Reference No.	E-244-1997/3-US-06

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

OTHER - NON-PATENT LITERATURE DOCUMENTS

Examiner Signature _____ Date Considered _____

- + A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).